Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Fineline Cube May 20, 2026
Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Fineline Cube May 20, 2026
Company Deals

Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo

Fineline Cube May 20, 2026
Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Fineline Cube May 19, 2026
Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study

Fineline Cube May 20, 2026
Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Fineline Cube May 20, 2026
Company

Henlius Biotech Posts 67.8% YOY Revenue Growth and First Annual Profit in 2023 Financials

Fineline Cube Mar 22, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696) has released its financial results for 2023, reporting revenues...

Company

Bayer Eliminates C-Level Roles in Restructuring Efforts to Boost Profitability

Fineline Cube Mar 22, 2024

Germany’s Bayer (ETR: BAYN) has taken significant steps in its restructuring efforts by eliminating 8...

Company Deals Digital

Baidu Health Partners with Yibang to Enhance Operations for Brick-and-Mortar Pharmacies

Fineline Cube Mar 21, 2024

Baidu Health has entered into a strategic partnership with Shanghai Yibang Medicine Information Technology Co.,...

Company Deals

Edan Instruments Partners with Global Health Labs to Develop AI-Enhanced Handheld Ultrasound

Fineline Cube Mar 21, 2024

Shenzhen-based Edan Instruments Inc. has forged a strategic partnership with Global Health Labs Inc. to...

Company Drug

FDA Grants Accelerated Approval for Takeda’s Iclusig in Newly Diagnosed Ph+ ALL

Fineline Cube Mar 21, 2024

The U.S. Food and Drug Administration (FDA) has granted accelerated indication extension approval to Japan’s...

Policy / Regulatory

China Unveils Action Plan to Boost Foreign Investment and Open Economy Further

Fineline Cube Mar 21, 2024

The State Council of China has unveiled an ambitious “Action Plan to Promote the High-Level...

Company

Simcere Pharmaceutical Reports 4.5% Revenue Growth in 2023 Amid Shifts in Profitability

Fineline Cube Mar 21, 2024

Simcere Pharmaceutical Group (HKG: 2096), based in China, has released its 2023 financial performance report,...

Company Deals

Sinopharm and Fresenius Kabi Expand Partnership to Enhance Drug Distribution and Healthcare Services

Fineline Cube Mar 21, 2024

China’s state-owned Sinopharm Group Co., Ltd. (HKG: 1099) has announced a new partnership with Germany’s...

Company Deals

Bayer and Thermo Fisher Partner to Develop Rapid Companion Diagnostics for Precision Oncology

Fineline Cube Mar 21, 2024

Germany’s Bayer (NYSE: BAYE) has entered into a strategic partnership with U.S. life sciences leader...

Company Drug

iRegene’s NouvSight001 Gains Orphan Drug Designation for Retinitis Pigmentosa Treatment

Fineline Cube Mar 21, 2024

Wuhan-based cell therapy innovator iRegene has secured Orphan Drug Designation (ODD) from the U.S. FDA...

Company Drug

BMS Reports Positive Phase III Results for Opdivo and Yervoy in Advanced HCC

Fineline Cube Mar 21, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) announced this week that its Phase III study evaluating...

Company Deals

China Resources Guangdong Pharmaceutical Partners with BD to Enhance Drug and Device Distribution in GBA

Fineline Cube Mar 21, 2024

China Resources Guangdong Pharmaceutical Co., Ltd has entered into a strategic partnership with U.S.-based Becton,...

Digital R&D

CAIR Launches CARES Copilot 1.0: A Revolutionary AI Chatbot for Medical Diagnosis and Treatment

Fineline Cube Mar 21, 2024

The Centre for Artificial Intelligence and Robotics (CAIR), part of the Chinese Academy of Sciences...

Company Deals

VIVA Biotech Secures Licensing Deal with Lonza for Advanced Bispecific Antibody Technology

Fineline Cube Mar 21, 2024

VIVA Biotech Holdings (HKG: 1873), a China-based Contract Research Organization (CRO), has entered into a...

Company Drug

Antengene’s ATG-022 Advances to Dose Expansion Phase in Phase II CLINCH Study for Solid Tumors

Fineline Cube Mar 21, 2024

Antengene Corporation Ltd (HKG: 6996), a leading biopharmaceutical company based in China, has announced that...

Company Drug

CSPC Pharmaceutical Secures NMPA Approval for Clinical Study of SYS6023 in Advanced Solid Tumors

Fineline Cube Mar 21, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a prominent China-based biopharmaceutical company, has received approval from...

Company

3SBio Reports 13.8% Revenue Growth in 2023, Driven by Strong Sales of Core Biologics

Fineline Cube Mar 21, 2024

3SBio Inc. (HKG: 1530), a leading China-based biopharmaceutical company, has reported its 2023 financial results,...

Company

Innovent Biologics Reports 36.2% Revenue Growth in 2023, Highlights Robust Product Sales

Fineline Cube Mar 21, 2024

Innovent Biologics Inc. (HKG: 1801), a China-based biotechnology firm, has released its 2023 financial report,...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for Phase Ib/II Study of HRS2398 in Advanced Solid Tumors

Fineline Cube Mar 20, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Deals

Zuellig Pharma Expands Commercialization Deal for Karo Healthcare’s Lamisil in Asian Markets

Fineline Cube Mar 20, 2024

Zuellig Pharma, a Singapore-based healthcare solutions provider, has announced the expansion of its commercialization agreement...

Posts pagination

1 … 389 390 391 … 669

Recent updates

  • CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus
  • Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study
  • Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law
  • Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study
  • China Population Welfare Foundation and Lilly China Launch “Tuohu Chang’an” Patient Assistance Program for Inflammatory Bowel Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Company Drug

Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study

Others

Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law

Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.